A tablet treatment for obesity may seem simpler than an injection. But for patients affected by Wegovy, the real question is first and foremost financial: the oral form is not reimbursed at this stage, unlike certain conditionally injectable forms.
This difference changes access to the medication, without making it a trivial treatment or a solution to be sought without medical advice.
What changes with Wegovy tablet
Wegovy is a semaglutide-based medication indicated in the treatment of obesity. Its new oral form is listed by Vidal as marketed in several dosages, in boxes of 30 tablets, with the mention not reimbursed by Social Security. The European Medicines Agency also reminds that these tablets are available only by prescription.
Concretely, the arrival of Wegovy in tablets can remove a practical constraint for certain people: no longer using an injectable pen. But that doesn’t change its status. This is a medicine against obesity, intended for a limited public and supervised medicallynot freely accessible slimming aid.
According to information provided by Novo Nordisk, the recommended price starts at €169 for a one-month box. This amount is not a regulated price: the actual price charged may vary depending on the pharmacy and the dosage. For non-reimbursed treatment, this difference can quickly become decisive.
Why does health insurance not cover it?
The central point is not an adverse medical decision made public on the tablet. According to The Parisianthe High Authority for Health confirms that Novo Nordisk has not submitted a request for reimbursement for the oral form. However, the Ministry of Health describes a clear circuit: without request from the company, the refund process cannot be initiated.
When a request exists, the Transparency Commission assesses in particular the actual benefit, the available data, the adverse effects and the alternatives. Then, the price is discussed with the Economic Committee for Health Products, then the coverage rate is fixed. This negotiation results in a controlled price, which reduces the freedom to set the price compared to a non-reimbursed product.
Le Parisien reports two readings of this choice. Novo Nordisk highlights the desire to allow supervised access and to prevent patients from turning to unauthorized circuits. People cited in the daily newspaper evoke commercial hypotheses, such as the desire not to compete with the injectable version or to avoid negotiating a lower price. These avenues remain analyses, not proof of laboratory intent.
What this means for affected patients
The comparison with the injectable form is important. Certain injectable presentations of Wegovy are now reimbursable, with 65% coverage by health insuranceunder strict conditions. Remember that the treatment is aimed at situations of very severe obesity and requires a prescription from a specialized doctor. To understand this framework, the detailed criteria of Wegovy’s reimbursement conditions are decisive.
For the tablet, the absence of reimbursement means full liability. This is what can lead some patients to reject it, even if oral intake seems more acceptable to them than injection. Professor Antoine Avignon, head of the nutrition-diabetes unit at Montpellier University Hospital, sums up to Le Parisien: “When we tell them that it will not be reimbursed, many exclude it”.
The risk, in this context, is twofold: creating strong expectations around a more practical form, then making access very unequal depending on financial means. Another point of vigilance:
do not buy this type of medication without a prescription or outside the authorized circuitespecially online. Obesity treatments are part of the medical management of obesity, with appropriate monitoring, and not as a product to be tested alone.